Medicine
Velcade 3.5 mg powder for injection
Velcade 3.5 mg powder for injection is a prescription medicine containing Bortezomib for intravenous, subcutaneous use, marketed by Takeda Pharmaceuticals, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Unopened vials may be stored at controlled room temperature 25°C (77°F)…
Key facts
- Active ingredient (INN)
- Bortezomib
- Brand
- Velcade
- Strength
- 3.5 mg
- Dosage form
- Powder for injection
- Route
- Intravenous, subcutaneous
- Packs
- 1 vial
- Marketing authorisation holder
- Takeda Pharmaceuticals
- Manufacturer
- Takeda Pharmaceuticals
- Origin register
- US FDA, United States
- Storage
- Unopened vials may be stored at controlled room temperature 25°C (77°F), excursions permitted from 15°C to 30°C (59°F to 86°F). Retain in original package to protect from light.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01XG01 Bortezomib
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 13 May 2003
- Identifiers
- RxCUI 402243, 402244DailyMed set ID 1521d321-e724-4ffc-adad-34bf4f44fac7NDC 63020-049Application NDA021602
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial in 1 carton / 1 injection, powder, lyophilized, for solution in 1 vial | 63020-049-01 | Takeda Pharmaceuticals | 13 May 2003 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Bortezomib 3.5 mg powder for injection.
Other strengths and forms of Bortezomib
Clinical summary
Bortezomib is a proteasome inhibitor indicated for treatment of adult patients with multiple myeloma treatment of adult patients with mantle cell lymphoma Multiple Myeloma VELCADE is indicated for the treatment of adult patients with multiple myeloma. MedsAcross supplies Bortezomib for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about BortezomibFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- VELCADE prescribing information (Takeda Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
- Velcade: European public assessment report (EPAR) · European Medicines Agency
- Bortezomib Accord: European public assessment report (EPAR) · European Medicines Agency
Need Velcade 3.5 mg powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.